Clin2
NCT05472337Possibly a fitRecruiting

Colchicine trial for better heart artery reopening after ACS

Acute Coronary Syndrome

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests whether colchicine (a medicine commonly used for inflammation) can improve how well clogged heart arteries reopen after a short-term heart emergency called ACS. You may be eligible if you’re hospitalized with ACS and are planned for a coronary angiogram and possible angioplasty soon.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You’re currently hospitalized for acute coronary syndrome (ACS), usually with chest pain and a blood test showing heart injury (troponin above normal).
  • A heart procedure called coronary angiography is planned during this hospital stay, with angioplasty expected soon.
  • You must be able and willing to sign written informed consent.
  • You’re not able to join if your ACS is an ST-elevation heart attack needing emergency angioplasty right away.
  • You must not have certain heart/liver/kidney problems, serious drug interactions, pregnancy or breastfeeding, or known colchicine intolerance.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06215989Recruiting
Low-dose colchicine for acute coronary syndrome

This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.

Beijing, Beijing Municipality
NCT06543082Recruiting· Phase 4
Study on heart attack patients with antiplatelet and colchicine therapy

This trial is for people who had a heart attack and received a specific type of stent (Orsiro). It tests a combination of a single antiplatelet drug and colchicine to see if it helps prevent future heart problems. Colchicine is a medicine that reduces inflammation and might lower the risk of another heart attack.

Seongnam-si, Gyeonggi-do
NCT07064109Recruiting
Colchicine for inflammation after heart attack

This trial tests if colchicine, an anti-inflammatory medicine, can help people who recently had a heart attack. It looks for markers in your blood to see who might benefit most.

Shanghai
NCT07349875Recruiting· Phase 4
Colchicine for non-severe coronary plaque: a trial

This trial tests if the anti-inflammatory drug colchicine can help people with non-severe coronary artery plaque seen on a CT scan. It may be an option if you have stable chest pain or related symptoms and your heart arteries are partly blocked but not severely.

Nanjing
NCT07362966Recruiting· Phase 4
Colchicine for heart health after a heart attack

This study tests whether a low-dose medicine called colchicine can reduce inflammation and slow down artery blockages in people who have a specific gene change (TET2) and have recently had a heart attack. The goal is to see if it helps prevent future heart problems.

Shenyang, Liaoning
NCT05175274Not yet recruiting· Phase 3
Colchicine to prevent heart artery disease in higher-risk adults

This trial tests whether taking colchicine can prevent coronary artery disease (heart artery blockages) in people who have several heart risk factors but do not already have diagnosed disease. It aims to see if colchicine lowers the chance of developing heart artery problems over time.

Qingdao, Shandong

Hear when a new Acute Coronary Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.